Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 7, 2014, Pages 1974-1984

  Dhalla, Shayesta ^a   Poole, Gary ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomedical prevention; Ethnicity willingness to participate; HIV; Race; Retention; Vaccines

Indexed keywords

EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TENOFOVIR; WART VIRUS VACCINE;

AFRICAN AMERICAN; CAUCASIAN; CONTROLLED STUDY; ETHNICITY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MINORITY GROUP; NORTH AMERICA; PHASE 3 CLINICAL TRIAL; PILOT STUDY; RACE; REIMBURSEMENT; REVIEW; SOCIAL PARTICIPATION; SOCIOECONOMICS; WART VIRUS; ANCESTRY GROUP; COMPARATIVE STUDY; ETHNIC GROUP; HIV INFECTIONS; MEDICATION COMPLIANCE; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; PHASE 3 CLINICAL TRIAL (TOPIC);

AIDS VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; NORTH AMERICA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE;

EID: 84908377252     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28870     Document Type: Review

References (67)

1. An Q, Prejean J, Hall HI. Racial disparity in U.S. diagnoses of acquired immune deficiency syndrome, 2000-2009. Am J Prev Med 2012; 43:461-6; PMID:23079167; http://dx.doi.org/10.1016/j.amepre.2012.07.040
2. Kraut-Becher J, Eisenberg M, Voytek C, Brown T, Metzger DS, Aral S. Examining racial disparities in HIV: lessons from sexually transmitted infections research. J Acquir Immune Defic Syndr 2008; 47:S20-7; PMID:18301130; http://dx.doi.org/10.1097/QAI.0b013e3181605b95
3. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al.; HVTN 505 Study Team. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083-92; PMID:24099601; http://dx.doi.org/10.1056/NEJMoa1310566
4. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93; PMID:19012954; http://dx.doi.org/10.1016/S0140-6736(08)61591-3
5. Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, Koblin B, Gurwith M, Bartholow B. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005; 39:359-64; PMID:15980699; http://dx.doi.org/10.1097/01.qai.0000152039.88422.ec
6. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65; PMID:15688278; http://dx.doi.org/10.1086/428404
7. Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep 2005; 120:543-8; PMID:16224987
8. Newman PA, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010; 24:1749-56; PMID:20597165; http://dx.doi.org/10.1097/QAD.0b013e32833adbe8
9. Hurley-Rosenblatt A, Dorsen C. Barriers to volunteer enrollment in HIV preventive vaccine clinical research trials: a review of the literature. J Assoc Nurses AIDS Care 2011; 22:330-4; PMID:21256768; http://dx.doi.org/10.1016/j.jana.2010.12.001
10. Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care 2011; 23:1430-47; PMID:21722022; http://dx.doi.org/10.1080/09540121.2011.555750
11. Dhalla S, Poole G. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. Vaccine 2011; 29:5850-9; PMID:21740947; http://dx.doi.org/10.1016/j.vaccine.2011.06.055
12. Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, Wilson K. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004; 18:2235-42; PMID:15577535; http://dx.doi.org/10.1097/00002030-200411190-00003
13. Newman PA, Duan N, Rudy ET, Anton PA. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS 2004; 18:691-701; PMID:15659880; http://dx.doi.org/10.1089/apc.2004.18.691
14. Tello J, Soong SJ, Hunter B, Meriwether R, Hook EW 3rd, Mulligan MJ. HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic. Am J Med Sci 1998; 315:11-6; PMID:9427569; http://dx.doi.org/10.1097/00000441-199801000-00003
15. Strauss RP, Sengupta S, Kegeles S, McLellan E, Metzger D, Eyre S, Khanani F, Emrick CB, MacQueen KM. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr 2001; 26:63-71; PMID:11176270; http://dx.doi.org/10.1097/00126334-200101010-00010
16. Brooks RA, Newman PA, Duan N, Ortiz DJ. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care 2007; 19:52-8; PMID:17129857; http://dx.doi.org/10.1080/09540120600872711
17. Moutsiakis DL, Chin PN. Why blacks do not take part in HIV vaccine trials. J Natl Med Assoc 2007; 99:254-7; PMID:17393949
18. Allen MA, Liang TS, La Salvia T, Tjugum B, Gulakowski RJ, Murguía M. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr 2005; 40:617-24; PMID:16284540; http://dx.doi.org/10.1097/01.qai.0000174655.63653.38
19. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, et al.; HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-19; PMID:18572080; http://dx.doi.org/10.1016/S0140-6736(08)60920-4
20. Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, Fernandez MI, Rutledge B, Martinez J, Garofalo R, et al.; Adolescent Trials Network for HIVAIDS Interventions (ATN). The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr 2013; 62:447-56; PMID:24135734; http://dx.doi.org/10.1097/QAI.0b013e3182801081
21. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99; PMID:21091279; http://dx.doi.org/10.1056/NEJMoa1011205
22. Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, O'hara B, Ackers ML, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013; 64:79-86; PMID:23466649; http://dx.doi.org/10.1097/QAI.0b013e31828ece33
23. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
24. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III doubleblind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5
25. Food and Drug Administration Package Insert (Cervarix) @ http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf. Accessed February 26, 2014.
26. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760
27. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
28. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401-11; PMID:21288094; http://dx.doi.org/10.1056/NEJMoa0909537
29. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576-85; PMID:22029979; http://dx.doi.org/10.1056/NEJMoa1010971
30. Food and Drug Administration Package Insert (Gardasil) @ http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf. Accessed February 26, 2014.
31. Sengupta S, Strauss RP, DeVellis R, Quinn SC, DeVellis B, Ware WB. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr 2000; 24:275-84; PMID:10969353; http://dx.doi.org/10.1097/00126334-200007010-00014
32. Seage GR 3rd, Holte SE, Metzger D, Koblin BA, Gross M, Celum C, Marmor M, Woody G, Mayer KH, Stevens C, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001; 153:619-27; PMID:11282787; http://dx.doi.org/10.1093/aje/153.7.619
33. Bartholow BN, MacQueen KM, Douglas JM Jr., Buchbinder S, McKirnan D, Judson FN. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:108-15; PMID:9358105; http://dx.doi.org/10.1097/00042560-199710010-00006
34. Koblin BA, Heagerty P, Sheon A, Buchbinder S, Celum C, Douglas JM, Gross M, Marmor M, Mayer K, Metzger D, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998; 12:785-93; PMID:9619811; http://dx.doi.org/10.1097/00002030-199807000-00015
35. Frew PM, Archibald M, Martinez N, del Rio C, Mulligan MJ. Promoting HIV vaccine research in African American communities: does the Theory of Reasoned Action explain potential outcomes of involvement? Challenge (Atlanta Ga) 2007; 13:61-97; PMID:20686675
36. Golub ET, Purvis LA, Sapun M, Safaeian M, Beyrer C, Vlahov D, Strathdee SA. Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users. AIDS Behav 2005; 9:301-9; PMID:16088366; http://dx.doi.org/10.1007/s10461-005-9004-3
37. Metch B, Frank I, Novak R, Swann E, Metzger D, Morgan C, Lucy D, Dunbar D, Graham P, Madenwald T, et al. Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. AIDS Behav 2013; 17:760-72; PMID:23090677; http://dx.doi.org/10.1007/s10461-012-0351-6
38. Strathdee SA, Hogg RS, Cornelisse PG, Martindale SL, Currie SL, O'Shaugnessy MV, Schechter MT. Factors associated with willingness to participate in HIV vaccine trials among HIV-negative injection drug users and young gay and bisexual men. AIDS Behav 2000; 4:271-8; http://dx.doi.org/10.1023/A:1009520802874
39. Meyers K, Metzger DS, McLellan AT, Navaline H, Sheon AR, Woody GE. Will preventive HIV vaccine efficacy trials be possible with female injection drug users? J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:577-85; PMID:8548338; http://dx.doi.org/10.1097/00042560-199510050-00012
40. Meyers K, Metzger DS, Navaline H, Woody GE, McLellan AT. HIV vaccine trials: will intravenous drug users enroll? Am J Public Health 1994; 84:761-6; PMID:8179045; http://dx.doi.org/10.2105/AJPH.84.5.761
41. Hays RB, Kegeles SM. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:164-71; PMID:10048904; http://dx.doi.org/10.1097/00042560-199902010-00009
42. Koblin BA, Avrett S, Taylor PE, Stevens CE. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:165-71; PMID:9241117; http://dx.doi.org/10.1097/00042560-199706010-00011
43. Gross M, Seage GR, Mayer KH, Goldstein RS, Losina E, Wold C. Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:406-12; PMID:8673551; http://dx.doi.org/10.1097/00042560-199608010-00012
44. Koblin BA, Holte S, Lenderking B, Heagerty P; The HIVNET Vaccine Preparedness Study Protocol Team. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. J Acquir Immune Defic Syndr 2000; 24:451-7; PMID:11035616; http://dx.doi.org/10.1097/00126334-200008150-00010
45. Brown-Peterside P, Rivera E, Lucy D, Slaughter I, Ren L, Chiasson MA, Koblin BA. Retaining hard-to-reach women in HIV prevention and vaccine trials: Project ACHIEVE. Am J Public Health 2001; 91:1377-9; PMID:11527761; http://dx.doi.org/10.2105/AJPH.91.9.1377
46. Brown-Peterside P, Chiasson MA, Ren L, Koblin BA. Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City. J Urban Health 2000; 77:425-37; PMID:10976615; http://dx.doi.org/10.1007/BF02386751
47. Buchbinder SP, Douglas JM Jr., McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis 1996; 174:954-61; PMID:8896495; http://dx.doi.org/10.1093/infdis/174.5.954
48. Koblin BA, Taylor PE, Avrett S, Stevens CE. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVE. AIDS Community Health Initiative Enroute to the Vaccine EFfort. AIDS 1996; 10:1555-61; PMID:8931792; http://dx.doi.org/10.1097/00002030-199611000-00015
49. Halpern SD, Metzger DS, Berlin JA, Ubel PA. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr 2001; 27:281-8; PMID:11464149; http://dx.doi.org/10.1097/00126334-200107010-00011
50. Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G, et al.; HVTN 906 Study Team. Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906. J Acquir Immune Defic Syndr 2013; 63:239-44; PMID:23446497; http://dx.doi.org/10.1097/QAI.0b013e31828ded1a
51. National Institute of Allergy and Infectious Diseases. QUESTIONS AND ANSWERS: HVTN 502 and HVTN 503 HIV Vaccine Clinical Trials @http://www.niaid.nih.gov/news/qa/pages/step-qa.aspx
52. Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, Koblin B, Marmor M, Bartholow BN, Popovic V; VAX004 Study Group. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2004; 37:1385-92; PMID:15483468; http://dx.doi.org/10.1097/01.qai.0000122983.87519.b5
53. HIV vaccine trials network. Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective http://www.hvtn.org/media/pr/step.html. Accessed February 26, 2014.
54. Koblin BA, Mayer KH, Noonan E, Wang CY, Marmor M, Sanchez J, Brown SJ, Robertson MN, Buchbinder SP. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr 2012; 60:405-13; PMID:22421748; http://dx.doi.org/10.1097/QAI.0b013e31825325aa
55. VaxGen trial social and behavioral data VAX report 2003; 1(1) Available from: http://www.vaxreport.org/Back-Issues/Pages/VaxGentrialsocialandbehavioraldata.aspx. Accessed April 1, 2014.
56. Newman PA, Duan N, Kakinami L, Roberts K. What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine 2008; 26:2528-36; PMID:18420313; http://dx.doi.org/10.1016/j.vaccine.2008.03.004
57. Newman PA, Duan N, Roberts KJ, Seiden D, Rudy ET, Swendeman D, Popova S. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr 2006; 41:210-7; PMID:16394854; http://dx.doi.org/10.1097/01.qai.0000179454.93443.60
58. Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, Hirsch A, Ippolito T, Luck A, Longhi M, et al. Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials. AIDS 2003; 17:147-56; PMID:12545073; http://dx.doi.org/10.1097/00002030-200301240-00003
59. National Institutes of Health. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research - Amended, October, 2001 http://grants.nih.gov/grants/funding/women-min/guidelines-amended-10-2001.htm. Accessed February 26, 2014
60. Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:195-203; PMID:9390572; http://dx.doi.org/10.1097/00042560-199711010-00009
61. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492
62. Koblin BA, Mayer KH, Eshleman SH, Wang L, Mannheimer S, del Rio C, Shoptaw S, Magnus M, Buchbinder S, Wilton L, et al.; HPTN 061 Protocol Team. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One 2013; 8:e70413; PMID:23922989; http://dx.doi.org/10.1371/journal.pone.0070413
63. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801; PMID:19759533; http://dx.doi.org/10.1038/nature08463
64. McDaid LM, Hart GJ. Willingness to participate in future HIV prevention studies among gay and bisexual men in Scotland, UK: a challenge for intervention trials. AIDS Behav 2012; 16:1420-9; PMID:22101849; http://dx.doi.org/10.1007/s10461-011-0044-6
65. Dhalla S, Woods R, Strathdee SA, Patrick DM, Hogg RS. HIV vaccine preparedness studies in the organization for economic co-operation and development (OECD) countries. AIDS Care 2007; 19:1118-27; PMID:17851989; http://dx.doi.org/10.1080/09540120701352258
66. O'Connell JM, Hogg RS, Chan K, Strathdee SA, McLean N, Martindale SL, Willoughby B, Remis R. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr 2002; 31:521-8; PMID:12473841; http://dx.doi.org/10.1097/00126334-200212150-00010
67. Vlahov D, Astemborski J, Solomon L, Galai N, Basarab L, Nelson KE. Interest in HIV vaccines among injec tion drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S265-8; PMID:7865315